22 November 2021>: Clinical Research
Serum Beta-2 Microglobulin: A Possible Biomarker for Atrial Fibrillation
Bangying Zhang ABCDEF* , Xinpei Chen BCDE* , Xiaofeng Mu BDE* , Enzhao Liu AB , Tong Liu BE , Gang Xu BC , Qiankun Bao CDE , Guangping Li AFG*DOI: 10.12659/MSM.932813
Med Sci Monit 2021; 27:e932813
Table 2 Echocardiographic parameters of the study participants.
Control group n=61 | Atrial fibrillation n=60 | p-value | |
---|---|---|---|
LAD (mm) | 36.75±4.78 | 44.03±5.15** | |
LVEDD (mm) | 46.06±5.43 | 47.63±4.26 | 0.080 |
LVESD (mm) | 26.03±3.30 | 29.35±4.71** | |
IVST (mm) | 9.14±1.35 | 9.46±1.61 | 0.238 |
LVPWT (mm) | 9.13±1.28 | 9.41±1.45 | 0.257 |
RVAWT (mm) | 3.45±0.53 | 3.62±0.51 | 0.071 |
RVDD (mm) | 20.68±2.28 | 21.43±3.64 | 0.176 |
LVEF (mm) | 64.21±4.92 | 62.57±5.35 | 0.081 |
LAD – left atrial anteroposterior diameter; LVEDD – left ventricular end-diastolic diameter; LVESD – left ventricular end-systolic diameter; IVST – interventricular septum thickness; LVPWT – left ventricular posterior wall thickness; RVAWT – right ventricular anterior wall thickness; RVEDD – right ventricular end-diastolic diameter; LVEF – left ventricular ejection fraction. Data are means±standard deviation (SD). ** |